⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thiouracil SCHEMBL9172 | 1.00 | — | — | |
| Thiouracil SCHEMBL27922231 | 0.97 | — | — | |
| Thiouracil SCHEMBL30091289 | 0.97 | — | — | |
| Uracil SCHEMBL28120281 | 0.91 | TP53 (0.83) | — | |
| Thiouracil SCHEMBL7804101 | 0.89 | TP53 (0.79) | — | |
| Thiouracil SCHEMBL27970384 | 0.87 | TP53 (0.76) | — | |
| Thiouracil SCHEMBL28095966 | 0.87 | TP53 (0.76) | — | |
| Thiouracil SCHEMBL28205719 | 0.85 | TP53 (0.73) | — | |
| Thiouracil SCHEMBL4958659 | 0.81 | TP53 (0.66) | — | |
| Thiouracil SCHEMBL22345877 | 0.80 | TP53 (0.63) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| EP-1499627-A2 | NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES | ISIS Pharmaceuticals, Inc. (US) | 2005-01-26 | — | — | EP | claimed |
| WO-2004094345-A2 | PROTECTED MONOMERS | ALNYLAM PHARMACEUTICALS INC. (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040033973-A1 | Compounds and oligomeric compounds comprising novel nucleobases | ISIS PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | claimed |
| US-20030207804-A1 | Modified peptide nucleic acids | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | claimed |
| US-20030175906-A1 | Nuclease resistant chimeric oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | claimed |
| US-20030158403-A1 | Nuclease resistant chimeric oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | claimed |
| WO-2003004602-A2 | NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | claimed |
| WO-2002097134-A2 | MODIFIED PEPTIDE NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | claimed |
| US-20220403377-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-11530408-B2 | Therapeutic compositions | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-11312957-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210254065-A1 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| WO-2004090108-A2 | IRNA CONJUGATES | ALNYLAM PHARMACEUTICALS (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004080406-A2 | THERAPEUTIC COMPOSITIONS | ALNYLAM PHARMACEUTICALS (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040033973-A1 | Compounds and oligomeric compounds comprising novel nucleobases | ISIS PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
| US-20030207804-A1 | Modified peptide nucleic acids | ISIS PHARMACEUTICALS, INC. | 2003-11-06 | — | — | US | disclosed |
| WO-2002097134-A2 | MODIFIED PEPTIDE NUCLEIC ACID | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-05 | — | — | WO | disclosed |